BRAF and colonic neoplasm: Our data revealed that a co-treatment with vemurafenib and ABC294640 significantly reduced cellular levels of S1P in comparison with either drug alone, which again confirms that the aberrant regulation of S1P metabolism might be a hallmark of drug resistance in BRAF mutant colon cancer cells.